PMID- 36262804
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221101
IS  - 1178-6930 (Print)
IS  - 1178-6930 (Electronic)
IS  - 1178-6930 (Linking)
VI  - 15
DP  - 2022
TI  - Anlotinib Hydrochloride and PD-1 Blockade as a Salvage Second-Line Treatment in 
      Patients with Progress of Local Advanced Non-Small Cell Lung Cancer in Half a 
      Year After Standard Treatment.
PG  - 1221-1228
LID - 10.2147/OTT.S380615 [doi]
AB  - PURPOSE: As for local advanced non-small cell lung cancer (NSCLC), synchronous 
      radiotherapy and chemotherapy is the standard treatment mode. But for patients 
      with progress in half a year, which means the second-line chemotherapy effect is 
      not ideal for them. We observed the efficacy and safety of anlotinib 
      hydrochloride combined with PD-1 blockade as the second-line treatment for those 
      patients in this trial. PATIENTS AND METHODS: From January 2018 to December 2019, 
      57 patients with the progress of local advanced NSCLC treated with anlotinib plus 
      PD-1 blockade until disease progression or intolerance as a result of adverse 
      events. Patients have been assessed using computed tomography prior to treatment 
      and during follow-up every 2 months until disease progression or death. The 
      primary endpoint was objective response rate (ORR). The secondary endpoints 
      included overall survival (OS), progression-free survival (PFS) and safety. 
      Survival curves were created using the Kaplan-Meier method. RESULTS: 57 patients 
      were enrolled. The median age was 64 years, and 61.4% of the patients were men. 
      The ORR was 50.9% with a median OS time of 14 months and the 1-year OS rates and 
      PFS rates were 81.8% and 33.3%, respectively. The patients with squamous cell 
      carcinoma, no brain or liver metastases had longer PFS than patients with liver 
      metastasis. When the PFS was calculated from the time of second treatment, the 
      median PFS was 9 months. Most adverse events (AEs) were grade 1-3, one 
      drug-related death was noted. CONCLUSION: The expected outcome of this study is 
      that anlotinib combined with PD-1 blockade has tolerable toxicity and better ORR, 
      OS than second-line chemotherapy. The results may indicate additional treatment 
      options for patients with progress of local advance NSCLC in half a year after 
      standard treatment.
CI  - (c) 2022 Yu et al.
FAU - Yu, Chengqi
AU  - Yu C
AD  - School of Basic Medical Science, Capital Medical University, Beijing, 100069, 
      People's Republic of China.
FAU - Jiang, Leilei
AU  - Jiang L
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of 
      Education/Beijing), Department of Radiation Oncology, Peking University Cancer 
      Hospital and Institute, Beijing, People's Republic of China.
FAU - Yang, Dan
AU  - Yang D
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of 
      Education/Beijing), Department of Radiation Oncology, Peking University Cancer 
      Hospital and Institute, Beijing, People's Republic of China.
FAU - Dong, Xin
AU  - Dong X
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of 
      Education/Beijing), Department of Radiation Oncology, Peking University Cancer 
      Hospital and Institute, Beijing, People's Republic of China.
FAU - Yu, Rong
AU  - Yu R
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of 
      Education/Beijing), Department of Radiation Oncology, Peking University Cancer 
      Hospital and Institute, Beijing, People's Republic of China.
FAU - Yu, Huiming
AU  - Yu H
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of 
      Education/Beijing), Department of Radiation Oncology, Peking University Cancer 
      Hospital and Institute, Beijing, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20221017
PL  - New Zealand
TA  - Onco Targets Ther
JT  - OncoTargets and therapy
JID - 101514322
PMC - PMC9575589
OTO - NOTNLM
OT  - PD-1 blockade
OT  - angiogenesis
OT  - anlotinib
OT  - immunotherapy
OT  - local advanced non-small cell lung cancer
COIS- The authors report no conflicts of interest in this work.
EDAT- 2022/10/21 06:00
MHDA- 2022/10/21 06:01
PMCR- 2022/10/17
CRDT- 2022/10/20 02:45
PHST- 2022/07/04 00:00 [received]
PHST- 2022/10/01 00:00 [accepted]
PHST- 2022/10/20 02:45 [entrez]
PHST- 2022/10/21 06:00 [pubmed]
PHST- 2022/10/21 06:01 [medline]
PHST- 2022/10/17 00:00 [pmc-release]
AID - 380615 [pii]
AID - 10.2147/OTT.S380615 [doi]
PST - epublish
SO  - Onco Targets Ther. 2022 Oct 17;15:1221-1228. doi: 10.2147/OTT.S380615. 
      eCollection 2022.